Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2014, Vol. 19 ›› Issue (11): 1306-1311.
Previous Articles Next Articles
QIAO Ai-min, LI Le, LIU Qing
Received:
2014-01-02
Revised:
2014-07-29
Online:
2014-11-26
Published:
2014-12-09
CLC Number:
QIAO Ai-min, LI Le, LIU Qing. Mechanism of action of advanced glycation end products and their receptors RAGE contribute to the development of diabetic vascular complications[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1306-1311.
Add to citation manager EndNote|Ris|BibTeX
URL: https://manu41.magtech.com.cn/Jweb_clyl/EN/
https://manu41.magtech.com.cn/Jweb_clyl/EN/Y2014/V19/I11/1306
[1] | Orasanu G, Plutzky J.The pathologic continuum of diabetic vascular disease[J].J Am Coll Cardiol, 2009, 53(5): 35-42. |
[2] | Schalkwijk CG, Miyata T.Early-and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics[J]. Amino acids, 2012, 42(4): 1193-1204. |
[3] | Yan SD, Schmidt AM, Anderson GM, et al.Enhanced cellular oxidant stress by the Interaction of advanced glycation end products with their receptors/Binding Proteins[J]. J Biol Chem, 1994, 269(13): 9889-9897. |
[4] | Yan SF, Ramasamy R, Schmidt AM.Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications[J]. Nat Rev Endocrinol, 2008, 4(5): 285-293. |
[5] | 程森华, 方朝晖. 氧化应激对糖尿病血管内皮的损伤机制及中医药干预研究[J]. 中医药临床杂志, 2012, 24(2): 163-165. |
[6] | Farmer DG, Kennedy S.RAGE, vascular tone and vascular disease[J]. Pharmacol Ther, 2009, 124(2): 185-194. |
[7] | Wautier MP, Chappey O, Corda S,et al.Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE[J]. Am J Physiol Endocrinol Metab, 2001, 280(5): E685-E694. |
[8] | Thallas-Bonke V, Thorpe SR, Coughlan MT, et al.Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-α-dependent pathway[J]. Diabetes, 2008, 57(2): 460-469. |
[9] | Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling[J]. Cardiovasc Res, 2009, 82(1):9-20. |
[10] | Basta G, Lazzerini G, Del Turco S, et al.At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products[J]. Arterioscler Thromb Vasc Biol, 2005, 25(7): 1401-1407. |
[11] | Liu Z, Cao W. p38 mitogen-activated protein kinase: a critical node linking insulin resistance and cardiovascular diseases in type 2 diabetes mellitus[J]. Endocr Metab Immune Disord Drug Targets, 2009, 9(1): 38-46. |
[12] | 何春玲, 邢文, 鲁柯兵, 等. 吡格列酮联用阿托伐他汀对2型糖尿病患者血脂及血管内皮功能的影响[J]. 中国临床药理学与治疗学, 2013, 18(2):198-201. |
[13] | Guo ZJ, Hou FF, Zhang X, et al.Advanced glycation end products inhibit production of nitric oxide by human endothelial cells through activation of the p38 signal pathway[J]. Natl Med J China, 2002, 82(19): 1328-1331. |
[14] | Chang PC, Chen TH, Chang CJ, et al.Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway[J]. Kidney Int, 2004, 65(5): 1664-1675. |
[15] | Guo XH, Huang QB, Chen B, et al.Advanced glycation end products induce actin rearrangement and subsequent hyperpermeability of endothelial cells[J]. Apmis, 2006, 114(12): 874-883. |
[16] | Sun C, Liang C, Ren Y, et al.Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways[J]. Basic Res Cardiol, 2009, 104(1): 42-49. |
[17] | Yeh CH, Sturgis L, Haidacher J, et al.Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappa B transcriptional activation and cytokine secretion[J]. Diabetes, 2001, 56(6): 1495-1504. |
[18] | Bierhaus A, Chevion S, Chevion M, et al.Advanced glycation end product-induced activation of NF-ΚB is suppressed byα-lipoic acid in cultured endothelial cells[J]. Diabetes, 1997, 46(9): 1481-1490. |
[19] | Haslbeck KM, Schleicher E, Bierhaus A, et al.The AGE/RAGE/NF-ΚB pathway may contribute to the pathogenesis of polyneuropathy in impaired giucose tolerance(IGT)[J]. Exp Clin Endocrinol Diabetes, 2005, 113(5): 288-291. |
[20] | BierhausA, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB[J]. Diabetes, 2001, 50(12): 2792-2808. |
[21] | 杨红艳, 陈婕, 陈思娇, 等. 2型糖尿病核因子κB信号通路相关微血管内皮损伤与SUMO化修饰[J]. 医学综述, 2012, 18(7): 1077-1080. |
[22] | Dandona P, Alijada A, Chaudhuri A, et al.Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation[J]. Ciculation, 2005, 111(11): 1448-1454. |
[23] | 蒲里津, 陆林, 沈卫峰. 晚期糖基化终末产物致动脉粥样硬化的机制[J]. 国际心血管病杂志, 2006, 33(2): 98-100. |
[24] | Xu B, Chibber R, Ruggiero D, et al.Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation endproducts[J]. FASEB J, 2003, 17(10): 1289-1291. |
[25] | Morigi M, Angioletti S, Imberti B, et al.Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion[J]. J Clin Invest, 1998, 101(9): 1905-1915. |
[26] | Barlovic D, Soro-Paavonen A, Jandeleit-Dahm K.RAGE biology, atherosclerosis and diabetes[J]. Clin Sci, 2011, 121(2): 43-55. |
[27] | Basta G, Schmidt AM, De Caterina R.Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes[J]. Cardiovasc Res, 2004, 63(4): 582-592. |
[28] | Wang Z, Jiang Y, Liu N, et al.Advanced glycation end-product N∈-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes[J]. Atherosclerosis, 2012, 221(2):387-396. |
[29] | Basta G, Schmidt AM, De Caterina R.Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes[J]. Cardiovasc Res, 2004, 63(4): 582-592. |
[30] | 戴丽, 杨芝春, 李元建. 糖基化终产物与糖尿病血管并发症[J]. 国际病理科学与临床杂志, 2012, 32(1): 30-34. |
[31] | 张劼, 李兴. 终末糖基化产物在糖尿病微血管病变中的作用[J]. 医学综述, 2007, 13(24): 1976-1977. |
[32] | Yokoi M, Yamagishi SI, Takeuchi M, et al.Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy[J]. Br J Ophthalmol, 2005, 89(6): 673-675. |
[33] | Patel S, Santani D.Role of NF-kB in the pathogenesis of diabetes and its associated complications[J]. Pharmacol Rep, 2009, 61(595): 595-603. |
[34] | 李碧慧, 林少达. 可溶性晚期糖基化终产物受体与糖尿病慢性并发症[J]. 中华临床医师杂志, 2011, 5(16): 4802-4804. |
[35] | Bucala R, Vlassara H, Helen Vlassara.Advanced glycosylation end products in diabetic renal and vascular disease[J]. Am J Kidney Dis, 1995, 26(6): 875-888. |
[36] | Kanwar YS, Sun L, Xie P, et al.A glimpse of various pathogenetic mechanisms of diabetic nephropathy[J]. Annu Rev Pathol, 2011, 6: 395-423. |
[37] | Chung AC, Zhang H, Kong YZ, et al.Advanced Glycation End-Products Induce Tubular CTGF via TGF-β-Independent Smad3 Signaling[J]. J Am Soc Nephrol, 2010, 21(2): 249-260. |
[38] | 黄达明, 张志才, 连宾. 22种中药醇提物抑制蛋白质非酶糖基化作用的研究[J]. 食品科学, 2007, 28(5): 41-44. |
[39] | 符丽娟, 杨育红. 槲皮素对糖尿病大鼠心肌非酶糖基化及细胞凋亡的影响[J]. 中国现代医学杂志, 2011, 21(5): 552-555. |
[40] | Shen JG, Yao MF, Chen XC, et al.Effects of puerarin on receptor for advanced glycation end products in nephridial tissue of streptozotocin-induced diabetic rats[J]. Mol Biol Rep, 2009, 36(8): 2229-2233. |
[41] | 殷桂香, 曹玉莉, 朱德增. 酸味中药复方对2型糖尿病大鼠主动脉 AGEs 含量及受体基因表达的影响[J]. 中国中西医结合杂志, 2009, 29(8): 725-728. |
[42] | Kim J, Kim KM, Kim CS, et al.Puerarin inhibits the retinal pericyte apoptosis induced by advanced glycation end products in vitro and in vivo by inhibiting NADPH oxidase-related oxidative stress[J]. Free Radic Biol Med, 2012, 53(2): 357-365. |
[43] | 孙承波, 梁春, 吴宗贵, 等. 通心络对晚期糖基化终产物诱导的内皮祖细胞存活的影响及机制[J]. 上海医学, 2008, 31(10): 711-714. |
[44] | 向敏, 王建梅, 周成华, 等. 西红花酸对AGEs诱导血管内皮细胞通透性增加的抑制作用[J]. 中国药理学通报, 2011, 27(9): 1254-1259. |
[45] | 陈放, 刘开扬, 徐珊. 葛根素对糖尿病大鼠视网膜的保护及对NF-κB表达的抑制[J]. 中国药理学与毒理学杂志, 2011, 25(3): 296-300. |
[46] | Ceriello A, Ihnat MA, Thorpe JE.The “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications[J]? J Clin Endocrinol Metab,2009, 94(2): 410-415. |
[1] | QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili. New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687. |
[2] | HU Kangyi, CAO Linzhong, WAN Chaochao, SHANG Zhengya, YANG Xiaorui, ZHANG Yongjie. Research progress of traditional Chinese medicine regulating mitochondrial function in the treatment of steroid-induced femoral head necrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 688-696. |
[3] | QIN Wenxiu, XU Junfeng, YANG Ting, WANG Pingfei. Research progress on signaling pathway of tanshinoneIIA in treatment of nerve injury after ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 705-713. |
[4] | LI Yanyang, WANG Yunjiao, LV Shichao. Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577. |
[5] | LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593. |
[6] | QI Xiaofeng, LUO Yali, XIAO Mengyong, ZHOU Shiqin, ZHOU Wen, AN Fangyu, WEI Benjun, LIU Yongqi. Research status of dialectical prevention and treatment of acute lung injury based on the theory of "Wei qi and Ying Xue" [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 429-437. |
[7] | CHEN Shengfu, LI Xiaolin, WANG Weigang, DU Weize, LI Maoxing. Research progress on antipyretic effect of Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 334-344. |
[8] | WANG Wenjuan, QI Mingrui, TIAN Limin. Research progress on Nrf2 in diabetic cardiomyopathy and intervention of traditional Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1163-1170. |
[9] | CHEN Ying, YUAN Yonggui. Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593. |
[10] | YIN Yujie, CHANG Liping. Pharmacological research and clinical applications progress of Lianhua Qingwen capsules/granules in respiratory diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1174-1180. |
[11] | MU Xin, ZHAO Ying, ZHANG Lan, CUI Yimin, ZHANG Yongxiang, DU Guanhua. Drug clinical trial of COVID-19 in China: A brief analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 869-877. |
[12] | FENG Rui, ZHANG Jiali, HE Mingchao, LI Yue, ZHANG Yan. Pharmacological targets and clinical application of traditional Chinese medicine and active components in the prevention and treatment for depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 467-474. |
[13] | LU Yubao, CHEN Yutong, HE Gege, CAI Zongyan, CHENG Yue, CHENG Zihua, GUO Jiamin, GUO Yanzhi. Application of traditional Chinese medicine extract in repairing spinal cord injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1075-1080. |
[14] | FAN Qilin,ZHENG Xiao,WANG Shumei,HAO Haiping,LI Ping. Abnormal regulation of autophagy in inflammatory bowel disease and the intervention of traditional Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 471-480. |
[15] | SHEN Bin,JIANG Liya,WANG Xiaoling,XU Longsheng,LU Xiaolei,HE Jiayang,SUN Peiyu,ZHOU Yuehong,ZHANG Xiaoping. Study and rationality evaluation on off-label drug use of traditional Chinese medicine injection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 223-227. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||